Fonar Announces Financial Results For The 1st Quarter of Fiscal 2026
FONAR (NASDAQ: FONR) reported 1Q fiscal 2026 results for the quarter ended September 30, 2025. Total revenues rose 4% to $26.0M, driven by the HMCA diagnostic-imaging segment at $23.5M and FONAR product/services at $2.5M (+14%).
Operating income fell 30% to $3.2M, consolidated net income fell 33% to $2.7M, and diluted EPS declined 26% to $0.34. SG&A increased 33% to $6.8M. Cash and short-term investments were $54.3M at September 30, 2025. HMCA reported scan volume of 55,106 (3.9% YoY growth).
FONAR (NASDAQ: FONR) ha riportato i risultati del primo trimestre dell'anno fiscale 2026 per il trimestre terminato il 30 settembre 2025. I ricavi totali sono aumentati del 4% a 26,0 milioni di dollari, trainati dal segmento HMCA diagnostica per immagini a 23,5 milioni e dai prodotti/servizi FONAR a 2,5 milioni (+14%).
Utile operativo è sceso del 30% a 3,2 milioni, l'utile netto consolidato è sceso del 33% a 2,7 milioni, e l'EPS diluito è diminuito del 26% a 0,34. SG&A è aumentata del 33% a 6,8 milioni. La cassa e gli investimenti a breve termine sono stati 54,3 milioni di dollari al 30 settembre 2025. HMCA ha riportato un volume di scansione di 55.106 (crescita YoY del 3,9%).
FONAR (NASDAQ: FONR) informó los resultados del 1T del año fiscal 2026 para el trimestre terminado el 30 de septiembre de 2025. Los ingresos totales subieron un 4% a 26,0 millones de dólares, impulsados por el segmento HMCA de diagnóstico por imágenes en 23,5 millones y por productos/servicios de FONAR en 2,5 millones (+14%).
El ingreso operativo cayó un 30% a 3,2 millones, el ingreso neto consolidado cayó un 33% a 2,7 millones, y el BPA diluido cayó un 26% a 0,34. SG&A aumentó un 33% a 6,8 millones. Efectivo e inversiones a corto plazo fueron 54,3 millones al 30 de septiembre de 2025. HMCA reportó un volumen de escaneos de 55.106 (crecimiento interanual del 3,9%).
FONAR (NASDAQ: FONR)는 2025년 9월 30일 종료된 분기의 2026 회계연도 1분기 실적을 발표했습니다. 총 매출은 HMCA 진단 영상 부문이 23.5백만 달러, FONAR 제품/서비스가 2.5백만 달러로(+14%) 상승하여 2600만 달러에 도달했습니다.
영업이익은 30% 하락한 320만 달러, 연결 순이익은 33% 감소한 270만 달러, 그리고 희석 주당순이익은 26% 감소한 0.34달러로 떨어졌습니다. SG&A는 33% 상승하여 680만 달러였습니다. 현금 및 단기투자액은 2025년 9월 30일 기준 5430만 달러였습니다. HMCA의 스캔 건수는 55,106건으로 YoY 증가율은 3.9%입니다.
FONAR (NASDAQ: FONR) a publié les résultats du premier trimestre de l'année fiscale 2026 pour le trimestre clos le 30 septembre 2025. Les revenus totaux ont augmenté de 4% pour atteindre 26,0 millions de dollars, soutenus par le segment HMCA d'imagerie diagnostique à 23,5 millions et par les produits/services FONAR à 2,5 millions (+14%).
Le résultat opérationnel a diminué de 30% à 3,2 millions, le résultat net consolidé a chuté de 33% à 2,7 millions, et le bénéfice par action dilué a reculé de 26% à 0,34 $. Les SG&A ont augmenté de 33% à 6,8 millions. La trésorerie et les investissements à court terme s'élevaient à 54,3 millions de dollars au 30 septembre 2025. HMCA a enregistré un volume de scans de 55 106 (croissance annuelle de 3,9%).
FONAR (NASDAQ: FONR) berichtete die Ergebnisse des ersten Quartals des Geschäftsjahres 2026 für das Quartal zum 30. September 2025. Gesamtumsätze stiegen um 4% auf 26,0 Mio. $, getrieben vom HMCA-Diagnose-Bildgebungssegment mit 23,5 Mio. $ und FONAR-Produkten/-Dienstleistungen mit 2,5 Mio. $ (+14%).
Betriebsergebnis fiel um 30% auf 3,2 Mio. $, Nettoergebnis sank um 33% auf 2,7 Mio. $, und verwässerter Gewinn pro Aktie ging um 26% auf 0,34 $ zurück. SG&A stieg um 33% auf 6,8 Mio. $. Barkapital und kurzfristige Anlagen beliefen sich am 30. September 2025 auf 54,3 Mio. $. HMCA meldete ein Scan-Volumen von 55.106 (YoY-Wachstum von 3,9%).
FONAR (NASDAQ: FONR) أعلنت عن نتائج الربع الأول للسنة المالية 2026 للربع المنتهي في 30 سبتمبر 2025. الإيرادات الإجمالية ارتفعت بنسبة 4% لتصل إلى 26.0 مليون دولار، مدفوعة بقطاع HMCA لتشخيص الصور بـ 23.5 مليون دولار وبمنتجات/خدمات FONAR بـ 2.5 مليون دولار (+14%).
الدخل التشغيلي انخفض بنسبة 30% إلى 3.2 مليون دولار، وانخفض صافي الدخل المجمع بنسبة 33% إلى 2.7 مليون دولار، وتراجع ربحية السهم المخفف بنسبة 26% إلى 0.34 دولار. ارتفعت SG&A بنسبة 33% إلى 6.8 مليون دولار. كانت النقدية والاستثمارات قصيرة الأجل 54.3 مليون دولار في 30 سبتمبر 2025. أعلن HMCA عن حجم فحص المسح بإجمالي 55,106 (نمو سنوي قدره 3.9%).
- Total revenues +4% to $26.0M in 1Q FY2026
- HMCA revenue +3% to $23.5M for the quarter
- FONAR segment revenue +14% to $2.5M
- HMCA scan volume 55,106, +3.9% YoY
- Selling, general & administrative expenses +33% to $6.8M
- Income from operations -30% to $3.2M
- Consolidated net income -33% to $2.7M
- Diluted EPS -26% to $0.34
Insights
Revenue ticked up but profitability fell; management pursues a going‑private proposal while pausing buybacks.
FONAR generated
The business model remains centered on diagnostic imaging management via HMCA, which reported scan volume of 55,106 for the quarter (a
Key near-term items to monitor include the Special Committee’s negotiation outcomes and any definitive agreement or proxy filing (timing unspecified), resumption or permanent cessation of the repurchase plan, and operational milestones such as the planned addition of a second MRI at a Nassau County center in the
Cash and cash equivalents decreased
4% to$54.3 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025.Total Revenues - Net increased by
4% to$26.0 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Income from Operations decreased
30% to$3.2 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Consolidated Net Income decreased
33% to$2.7 million for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Diluted Net Income per Common Share decreased
26% to$0.34 for the quarter ended September 30, 2025 versus the corresponding quarter one year earlier.Working Capital decreased by
0.3% to$127.1 million at September 30, 2025 as compared to the fiscal year-ended June 30, 2025.On September 13, 2022, the Company adopted a stock repurchase plan of up to
$9 million . At September 30, 2025, the Company has purchased over 283,770 shares at a cost of$6.1 million .
Melville, New York--(Newsfile Corp. - November 10, 2025) - FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported today its financial results for the first quarter of fiscal 2026 which ended September 30, 2025. FONAR's primary source of income is attributable to its wholly-owned diagnostic imaging management subsidiary, Health Management Company of America (HMCA). In 2009, HMCA managed 9 MRI scanners. Currently, HMCA manages 44 MRI scanners in New York and in Florida.
Financial Results
Revenues from the FONAR segment, which includes Product Sales, Upgrades, Service and Repair Fees, for related and non-related medical parties, increased
Revenues, from the Health Management Corporation of America (HMCA) segment, increased by
Total Revenues - Net increased by
Selling, general and administrative (S, G & A) expenses increased
Total Costs and Expenses increased
Income from Operations decreased
Consolidated Net Income decreased
Diluted Net Income per Common Share available to common shareholders decreased
The weighted average diluted shares outstanding attributable to common stockholders for the quarter ended September 30, 2025 was 6.3 million versus 6.4 million for the quarter ended September 30, 2024.
Balance Sheet Items
Total Cash and Cash Equivalents and Short Term Investments at September 30, 2025 decreased
Total Assets at September 30, 2025 were
Total Liabilities at September 30, 2025 were
Total Current Assets at September 30, 2025 were
Total Current Liabilities at September 30, 2025 were
Total Equity was
The Current Ratio was 8.6 at September 30, 2025 as compared to 8.4 at June 30, 2025.
The ratio of Total Assets/Total Liabilities was 3.8 at September 30, 2025 and at June 30, 2025.
Net Book Value per Common Share was
Cash Flow Item
Net Cash Flow provided by Operating activities was
Management Discussion
Timothy Damadian, Chairman and CEO of FONAR, said, "Our diagnostic imaging management subsidiary, Health Management Company of America (HMCA), the Company's primary source of revenue and profit, continues to grow. Scan volume in the first quarter of Fiscal 2026 was 55,106. Although
"We're off to a good start and expect to continue growing throughout the year. One of the Stand-Up MRI centers we manage in Nassau County will be adding a second MRI in the second quarter. We're also planning on managing an entirely new MRI center, also in Nassau County, later in the fiscal year. As always, we continue to search for locations where the introduction of our technology and services would profitably enhance our existing New York and Florida networks."
"The addition of second, or even third, scanners at existing STAND-UP® MRI centers had been very successful. Typically installed at busy centers, these additional MRIs immediately reduce scheduling backlogs, making these centers very attractive to both referring physicians and patients."
"These additional MRIs are typically high-field MRIs, which are very useful for instances where high-resolution imaging or certain advanced applications are required. They complement STAND-UP® MRIs perfectly. STAND-UP® MRIs are the most patient-friendly MRIs, the only MRIs that can scan patients in weight-bearing positions, and the only MRIs that can spines in flexion and extension. Since centers with both a STAND-UP® MRI and a high-field MRI are able to meet a very broad range of MRI needs, referring physicians know that whatever type of MRI their patients require, these centers can meet their needs, and without delay."
"As previously reported, on July 7, 2025, the board of directors received a non-binding proposal from a group led by me, the Company's Chief Executive Officer, and Luciano Bonanni, the Company's Chief Operating Officer, pursuant to which the group would acquire all of the outstanding common stock and other securities of the Company not currently owned by the members of the group. The Board of Directors has established a Special Committee of independent and disinterested directors to consider the proposal and negotiate on behalf of the Company and its stockholders. The Special Committee has retained its own independent financial and legal advisors to assist it in this process. The group and the Special Committee continue to be engaged in negotiations related to the proposed going private transaction, including a definitive price to be paid for the Company's securities and other related matters. No definitive agreements or terms have been executed by the parties and there is no assurance that the transaction will be completed. Any definitive agreement and transaction will require approval by the Company's common stock holders and will require the filing of definitive proxy materials in accordance with the SEC's proxy rules to obtain such approval."
Mr. Damadian continued, "In light of the ongoing negotiations related to the potential going private transaction, we have continued the suspension of share repurchases under our stock purchase plan that had been established in September, 2022."
Mr. Damadian concluded, "As always, I remain grateful to our management team and all of our employees for making our company a success."
About FONAR
FONAR, (NASDAQ: FONR) The Inventor of MR Scanning™, located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced MRI Company in the industry. FONAR went public in 1981. FONAR sold the world's first commercial MRI to Ronald J. Ross, MD, Cleveland, Ohio. It was installed in 1980. Dr. Ross and his team began the world's first clinical MRI trials in January 1981. The results were reported in the June 1981 edition of Radiology/Nuclear Medicine Magazine and the April 1982 peer-reviewed article in the Journal Radiology. The technique used for obtaining T1 and T2 values was the FONAR technique (Field fOcusing Nuclear mAgnetic Resonance), not the back projection technique. www.fonar.com/innovations-timeline.html.
FONAR's signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the STAND-UP® MRI), the only whole-body MRI that performs Position™ Imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® Multi-Position™ MRI often detects patient problems that other MRI scanners cannot because they are lie-down, "weightless-only" scanners. The patient-friendly UPRIGHT® MRI has a near-zero patient claustrophobic rejection rate. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately
FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body's neurologic system has been made possible first by FONAR's introduction of the MRI and now by this latest works-in-progress method for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries are among those who will benefit from this new understanding.
FONAR's primary source of income and growth is attributable to its wholly-owned diagnostic imaging management subsidiary, Health Management Company of America (HMCA) www.hmca.com.
FONAR's substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging of all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. It includes its newest technology for measuring the Upright cerebral hydraulics of the cerebrospinal fluid (CSF) of the central nervous system. FONAR's UPRIGHT® Multi-Position™ MRI is the only scanner licensed under these patents.
#
UPRIGHT®, and STAND-UP® are registered trademarks. The Inventor of MR Scanning™, CSP™, MultiPosition™, UPRIGHT RADIOLOGY™, pMRI™, CFS Videography™, Dynamic™ and The Proof is in the Picture™, are trademarks of FONAR Corporation.
This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.
Fonar Corporation
The Inventor of MR Scanning™
An ISO 9001 Company
Melville, New York 11747
Phone: (631) 694-2929
Fax: (631) 390-1772
NEWS
Contact: Daniel Culver
Director of Communications
E-mail: investor@fonar.com
www.fonar.com
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
ASSETS
| September 30, 2025 (Unaudited) | June 30, 2025 | |||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 54,276 | $ | 56,334 | ||||
| Short-term investments | 122 | 120 | ||||||
| Accounts receivable - net of allowances for credit losses of | 5,146 | 5,305 | ||||||
| Accounts receivable - related party | 90 | — | ||||||
| Medical receivable | 24,486 | 24,490 | ||||||
| Management and other fees receivable - net of allowances for credit losses of September 30, 2025 and June 30, 2025, respectively | 44,719 | 43,401 | ||||||
| Management and other fees receivable - related medical practices - net of allowances for credit losses of and | 10,027 | 9,748 | ||||||
| Inventories - net | 2,748 | 2,813 | ||||||
| Prepaid expenses and other current assets - related party | 530 | 411 | ||||||
| Prepaid expenses and other current assets | 1,591 | 2,050 | ||||||
| Total Current Assets | 143,735 | 144,672 | ||||||
| Accounts receivable - long term | 3,471 | 3,550 | ||||||
| Deferred income tax asset | 6,314 | 6,349 | ||||||
| Property and equipment - net | 19,449 | 18,532 | ||||||
| Note receivable - related party | 567 | 555 | ||||||
| Right-of-use-asset - operating leases | 36,122 | 35,136 | ||||||
| Right-of-use-asset - finance lease | 320 | 377 | ||||||
| Goodwill | 4,269 | 4,269 | ||||||
| Other intangible assets - net | 3,251 | 2,992 | ||||||
| Other assets | 854 | 476 | ||||||
| Total Assets | $ | 218,352 | $ | 216,908 | ||||
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
(Amounts and shares in thousands, except per share amounts)
LIABILITIES AND EQUITY
| September 30, 2025 (Unaudited) | June 30, 2025 | |||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 2,520 | $ | 1,302 | ||||
| Other current liabilities | 5,088 | 6,975 | ||||||
| Unearned revenue on service contracts | 4,711 | 4,866 | ||||||
| Unearned revenue on service contracts - related party | 83 | — | ||||||
| Operating lease liabilities - current portion | 3,668 | 3,383 | ||||||
| Finance lease liability - current portion | 244 | 244 | ||||||
| Customer deposits | 351 | 354 | ||||||
| Total Current Liabilities | 16,665 | 17,124 | ||||||
| Long-Term Liabilities: | ||||||||
| Unearned revenue on service contracts | 3,682 | 3,801 | ||||||
| Deferred income tax liability | 321 | 321 | ||||||
| Due to related party medical practices | 93 | 93 | ||||||
| Operating lease liabilities - net of current portion | 35,918 | 35,149 | ||||||
| Finance lease liability - net of current portion | 102 | 142 | ||||||
| Other liabilities | 176 | 173 | ||||||
| Total Long-Term Liabilities | 40,292 | 39,679 | ||||||
| Total Liabilities | 56,957 | 56,803 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
(Amounts and shares in thousands, except per share amounts)
LIABILITIES AND EQUITY (Continued)
| EQUITY: | September 30, 2025 (Unaudited) | June 30, 2025 | ||||||
| Class A non-voting preferred stock $.0001 par value; 453 shares authorized at September 30, 2025 and June 30, 2025, 313 issued and outstanding at September 30, 2025 and June 30, 2025 | $ | — | $ | — | ||||
| Preferred stock $.001 par value; 567 shares authorized at September 30, 2025 and June 30, 2024, issued and outstanding - none | — | — | ||||||
| Common Stock $.0001 par value; 8,500 shares authorized at September 30, 2025 and June 30, 2025, 6,203 issued at September 30, 2025 and June 30, 2025, 6,168 outstanding at September 30, 2025 and June 30, 2025, respectively | 1 | 1 | ||||||
| Class B Common Stock (10 votes per share) $.0001 par value; 227 shares authorized at September 30, 2025 and June 30, 2025, 0.146 issued and outstanding at September 30, 2025 and June 30, 2025 | — | — | ||||||
| Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at September 30, 2025 and June 30, 2025, 383 issued and outstanding at September 30, 2025 and June 30, 2025 | — | — | ||||||
| Paid-in capital in excess of par value | 178,757 | 178,757 | ||||||
| Accumulated deficit | (3,025) | (5,289) | ||||||
| Treasury stock, at cost - 35 shares of common stock at September 30, 2025 and at June 30, 2025 | (860) | (860) | ||||||
| Total FONAR Corporation's Stockholders' Equity | 174,573 | 172,609 | ||||||
| Noncontrolling interests | (13,478) | (12,504) | ||||||
| Total Equity | 161,395 | 160,105 | ||||||
| Total Liabilities and Equity | $ | 218,352 | $ | 216,908 |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts and shares in thousands, except per share amounts)
| For the Three Months Ended September 30, (Unaudited) | ||||||||
| Revenues | 2025 | 2024 | ||||||
| Patient fee revenue - net of contractual allowances and discounts | $ | 7,572 | $ | 7,487 | ||||
| Product sales | 316 | 120 | ||||||
| Service and repair fees | 2,182 | 1,992 | ||||||
| Service and repair fees - related parties | 45 | 45 | ||||||
| Management and other fees | 12,941 | 12,329 | ||||||
| Management and other fees - related medical practices | 2,987 | 2,987 | ||||||
| Total Revenues - Net | 26,043 | 24,960 | ||||||
| Cost and Expenses | ||||||||
| Costs related to patient fee revenue | 4,929 | 4,646 | ||||||
| Costs related to product sales | 324 | 221 | ||||||
| Costs related to service and repair fees | 1,059 | 1,091 | ||||||
| Costs related to service and repair fees - related parties | 8 | 67 | ||||||
| Costs related to management and other fees | 7,812 | 7,319 | ||||||
| Costs related to management and other fees - related medical practices | 1,464 | 1,573 | ||||||
| Research and development | 440 | 307 | ||||||
| Selling, general and administrative expenses | 6,813 | 5,130 | ||||||
| Total Costs and Expenses | 22,849 | 20,354 | ||||||
| Income from Operations | 3,194 | 4,606 | ||||||
| Other income and (expenses) | ||||||||
| Interest expense | (1) | (8) | ||||||
| Interest income - related party | 12 | 13 | ||||||
| Investment income | 474 | 639 | ||||||
| Other income (expense) | 3 | (1) | ||||||
| Income Before Provision for Income Taxes and Noncontrolling Interests | 3,682 | 5,249 | ||||||
| Provision for income taxes | (1,012) | (1,249) | ||||||
| Consolidated Net Income | 2,670 | 4,000 | ||||||
| Net Income - Noncontrolling Interests | (406) | (865) | ||||||
| Net Income - Attributable to FONAR | $ | 2,264 | $ | 3,135 | ||||
| Net Income Available to Common Stockholders | $ | 2,120 | $ | 2,939 | ||||
| Net Income Available to Class A Non-Voting Preferred Stockholders | $ | 108 | $ | 146 | ||||
| Net Income Available to Class C Common Stockholders | $ | 36 | $ | 50 | ||||
| Basic Net Income Per Common Share Available to Common Stockholders | $ | 0.34 | $ | 0.47 | ||||
| Diluted Net Income Per Common Share Available to Common Stockholders | $ | 0.34 | $ | 0.46 | ||||
| Basic and Diluted Income Per Share - Class C Common | $ | 0.10 | $ | 0.13 | ||||
| Weighted Average Basic Shares Outstanding - Common Stockholders | 6,169 | 6,304 | ||||||
| Weighted Average Diluted Shares Outstanding - Common Stockholders | 6,296 | 6,432 | ||||||
| Weighted Average Basic and Diluted Shares Outstanding - Class C Common | 383 | 383 | ||||||
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts and shares in thousands)
(UNAUDITED)
| For the Three Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Consolidated Net income | $ | 2,670 | $ | 4,000 | ||||
| Adjustments to reconcile consolidated net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 1,190 | 1,063 | ||||||
| Net change in operating right-of-use assets and lease liabilities | 125 | 237 | ||||||
| Provision (Recovery) for credit losses | 99 | (27) | ||||||
| Deferred tax expense | 35 | 866 | ||||||
| Changes in operating assets and liabilities, net: | ||||||||
| Accounts, medical and management fee receivable(s) | (1,544) | (278) | ||||||
| Notes receivable - related party | (12) | (13) | ||||||
| Inventories | 64 | (102) | ||||||
| Prepaid expenses and other current assets | 340 | (547) | ||||||
| Other assets | (378) | (11) | ||||||
| Accounts payable | 1,218 | (774) | ||||||
| Other current liabilities | (2,078) | (2,625) | ||||||
| Finance lease liabilities | (41) | (37) | ||||||
| Customer deposits | (3) | (98) | ||||||
| Other liabilities | 4 | 3 | ||||||
| Net cash provided by operating activities | 1,689 | 1,657 | ||||||
| Cash Flows from Investing Activities: | ||||||||
| Purchases of property and equipment | (1,866) | (1,805) | ||||||
| Cost of non-compete contract | (500) | — | ||||||
| Proceeds from short term investments | (1) | — | ||||||
| Cost of patents | — | (13) | ||||||
| Net cash used in investing activities | (2,367) | (1,818) | ||||||
| Cash Flows from Financing Activities: | ||||||||
| Repayment of borrowings and capital lease obligations | — | (26) | ||||||
| Purchase of treasury stock | — | (415) | ||||||
| Distributions to noncontrolling interests | (1,380) | (1,546) | ||||||
| Net cash used in financing activities | (1,380) | (1,987) | ||||||
| Net (Decrease) Increase in Cash and Cash Equivalents | (2,058) | (2,148) | ||||||
| Cash and Cash Equivalents - Beginning of Period | 56,334 | 56,341 | ||||||
| Cash and Cash Equivalents - End of Period | $ | 54,276 | $ | 54,193 | ||||
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273645
FAQ
What were FONR's total revenues for 1Q fiscal 2026?
How did FONR's net income and EPS change in 1Q FY2026?
What drove revenue growth at FONR in 1Q FY2026?
Why did FONR's operating income decline in 1Q FY2026?
What operational metrics did HMCA report for the quarter ended September 30, 2025?
What is the status of FONR's going-private proposal as of Nov 10, 2025?
